logo
Midnight Oil Drummer Rob Hirst Reveals Cancer Diagnosis

Midnight Oil Drummer Rob Hirst Reveals Cancer Diagnosis

Yahoo14-04-2025

Rob Hirst, the drummer of Australian rock veterans Midnight Oil, has revealed he is currently battling pancreatic cancer.
69-year-old Hirst, who co-founded the Sydney rock outfit in the '70s, revealed his diagnosis publicly in an interview with The Australian, explaining that he has been living with the disease for two years. Hirst noted he had received confirmation of his condition about six months after Midnight Oil wrapped up the Australian leg of their farewell tour in October 2023, and he's been receiving constant medical assistance since.
More from Billboard
Luis R. Conriquez Decries Concert Violence, Says 'I'll Make Significant Changes to My Lyrics'
Fans Choose Cynthia Erivo's 'Worst of Me' as This Week's Favorite New Music
Playboi Carti's 'MUSIC' Moves Back to No. 1 on Billboard 200 for Third Week
'So it's ongoing,' Hirst told the publication. 'I've had pretty much every treatment known to man – every scan, ultrasound, MRI. I've kind of had 'the works.''
Hirst explained that he was diagnosed 'early,' with his tumor being caught while at stage three. Upon learning of his condition, Hirst embarked upon months of chemotherapy before an unsuccessful eight-hour 'Whipple' surgery to attempt the removal of the tumor. He has since continued with both chemotherapy and radiotherapy.
Though initially keeping his diagnosis a secret, Hirst has since gone public to raise awareness of pancreatic cancer, noting that it 'hasn't really attracted the attention, for example, of skin cancers or breast cancers or others.' According to data from Cancer Australia, the average survival rate of individuals between 2016 and 2020 was 13%, with men given a chance of 12%.
'Coming up to two years, I thought I just need to get this, literally, off my chest,' Hirst explained. 'Also, I think that the lesson for me – and maybe why I've lasted this long – is because, if you do have any of that kind of symptom, where there's something that you feel is wrong, just go and get a simple blood test. It could be life-changing, and life-extending.'
Midnight Oil first formed in Sydney in 1972 as Farm, before adopting their later moniker in 1976. The group initially released eleven albums before splitting in 2002, with their breakthrough coming in 1982 with 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, which hit No. 3 in Australia.
Their following three albums – 1984's Red Sails in the Sunset, 1987's Diesel and Dust, and 1990's Blue Sky Mining – all topped the Australian charts, while the latter gave them a peak of No. 20 on the Billboard 200. Their 1987 single 'Beds Are Burning' is often considered a landmark of Australian music, with its message of Indigenous land rights also resonating internationally and peaking at No. 17 on the Hot 100.
While the band would be inducted into the ARIA Hall of Fame in 2006, they would reform a decade later in 2016, and following a global reunion tour, they issued The Makarrata Project in 2020 and Resist in 2022. While both albums would reach No. 1 in Australia, the former was released just one week before longtime bassist Bones Hillman passed from cancer at the age of 62.
Best of Billboard
Chart Rewind: In 1989, New Kids on the Block Were 'Hangin' Tough' at No. 1
Janet Jackson's Biggest Billboard Hot 100 Hits
H.E.R. & Chris Brown 'Come Through' to No. 1 on Adult R&B Airplay Chart

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Prince Kaybee opens up about amnesia struggle
Prince Kaybee opens up about amnesia struggle

News24

time6 hours ago

  • News24

Prince Kaybee opens up about amnesia struggle

Despite being a talented DJ and an award-winning artist, he is fearful of potentially missing out on opportunities due to his current medical condition. He previously gifted us with hit songs such as 'Charlotte,' 'Banomoya,' and 'Club Controller,' but he is now grappling with a new challenge—amnesia—which makes it difficult for him to remember his own life. Renowned South African DJ and music producer Kabelo Motsamai, popularly known for his stage name Prince Kaybee, recently shared his emotional struggle with serious memory loss, sparking a wave of public concern and support. In a heartfelt thread on X (formerly Twitter), Prince Kaybee revealed his growing fear of amnesia, sharing how it's slowly unravelling his life. He expressed frustration and emotional weight, saying, 'I suffer with serious amnesia, and I am a bit emotional and frustrated at how my memory is deteriorating, man. I am scared this will lead to missing life opportunities, which will make me very incompetent, and I hate that. I have some underlying condition affecting my brain (experts say), I wonder how long I can keep what is left of my memory bank.' Moreover, as a father, Prince Kaybee's condition is particularly daunting. He fears being unable to be present for his children, missing milestones, and failing to provide emotional guidance. He added, 'Not going to lie, this is rocking me, man. I have kids to raise.' Read more | Reality TV star Nozipho Ntshangase's husband, Zola Ntshangase, has taken a second wife Fans and followers have rallied around him, offering words of encouragement and practical tips on coping with memory loss, with some suggesting he documents daily tasks and thoughts in notebooks or phone apps to help stay organised. I suffer from SERIOUS AMNESIA and I am abit emotional and frustrated at how my memory is deteriorating man.💔 I am scared this will lead to missing life opportunities which will make me very incompetent and I HATE THAT. — K A B I L L I O N (@PrinceKaybee_SA) June 2, 2025

Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

Yahoo

time8 hours ago

  • Yahoo

Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22

NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Media: Michelle Lefler | VP, Communications & PR | media@ For Investors: ICR, Inc. | aurora@ Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. Sign in to access your portfolio

ASX Penny Stocks Spotlight: Biome Australia And Two Promising Picks
ASX Penny Stocks Spotlight: Biome Australia And Two Promising Picks

Yahoo

time14 hours ago

  • Yahoo

ASX Penny Stocks Spotlight: Biome Australia And Two Promising Picks

The Australian market continues to show strength, nearing record highs with sectors like energy leading the charge, despite some economic concerns such as a low GDP growth rate. For investors looking beyond the major players, penny stocks—commonly smaller or newer companies—remain an intriguing area of potential. While the term may seem outdated, these stocks can offer growth opportunities at lower price points when they possess strong financials and fundamentals. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.715 A$226.78M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.83 A$147.4M ★★★★☆☆ Accent Group (ASX:AX1) A$1.88 A$1.13B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.52 A$71.7M ★★★★★★ IVE Group (ASX:IGL) A$2.60 A$400.87M ★★★★★☆ GTN (ASX:GTN) A$0.63 A$120.24M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.49 A$165.6M ★★★★★★ Regal Partners (ASX:RPL) A$2.30 A$773.18M ★★★★★★ Tasmea (ASX:TEA) A$3.13 A$732.54M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.705 A$450.82M ★★★★★★ Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Biome Australia Limited focuses on developing, commercializing, and marketing live biotherapeutics and complementary medicines both in Australia and internationally, with a market cap of A$103.08 million. Operations: The company generates revenue of A$15.86 million from its segment focused on innovative evidence-based products that connect gut health with overall human health. Market Cap: A$103.08M Biome Australia Limited, with a market cap of A$103.08 million, has shown significant progress by becoming profitable this year and growing earnings at 29.8% per year over the past five years. Trading at 77.5% below its estimated fair value, it presents potential for investors seeking undervalued opportunities in the biotherapeutics sector. Despite negative operating cash flow and low return on equity at 6.4%, its short-term assets cover both short- and long-term liabilities effectively. The recent addition to the S&P/ASX Emerging Companies Index highlights increased visibility within investment circles, although management experience data remains insufficient for evaluation. Click here and access our complete financial health analysis report to understand the dynamics of Biome Australia. Explore Biome Australia's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hot Chili Limited, with a market cap of A$92.47 million, is a mineral exploration company operating in Chile. Operations: Hot Chili Limited does not have any reported revenue segments. Market Cap: A$92.47M Hot Chili Limited, with a market cap of A$92.47 million, is pre-revenue and focused on mineral exploration in Chile. Recent updates highlight the La Verde copper-gold discovery's potential, with assay results expanding the mineralisation footprint significantly. The identification of three look-alike targets suggests potential for a district-scale porphyry cluster. Despite being unprofitable and having less than a year of cash runway, Hot Chili's short-term assets exceed its liabilities, providing some financial stability. The company remains debt-free and has strengthened its board with experienced mining executives to guide strategic growth amid ongoing exploration activities at La Verde and Costa Fuego projects. Unlock comprehensive insights into our analysis of Hot Chili stock in this financial health report. Gain insights into Hot Chili's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PointsBet Holdings Limited operates a cloud-based platform offering sports, racing, and iGaming betting products and services in Australia, with a market cap of A$398.07 million. Operations: The company's revenue is derived from its Canadian trading segment, which generated A$36.24 million, and its Australian trading segment, contributing A$216.01 million. Market Cap: A$398.07M PointsBet Holdings, with a market cap of A$398.07 million, operates in the betting industry and is currently unprofitable but has reduced its losses at a rate of 27.1% annually over five years. The company is debt-free and its management team and board are experienced, with average tenures of 3.4 and 6.1 years respectively. Although trading below estimated fair value by 41.6%, the company's short-term assets (A$39.2M) fall short of covering its short-term liabilities (A$62.3M). Despite this, PointsBet has sufficient cash runway for more than three years based on current free cash flow trends. Jump into the full analysis health report here for a deeper understanding of PointsBet Holdings. Evaluate PointsBet Holdings' prospects by accessing our earnings growth report. Jump into our full catalog of 1,000 ASX Penny Stocks here. Searching for a Fresh Perspective? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BIO ASX:HCH and ASX:PBH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store